Table 1.
Population characteristics according to ART combination.
| Variable | Overall† | TDF + 3TC + DTG‡ | Other 1st line ARV‡ | ATVr or LPVr Based ARV‡ | P value* |
|---|---|---|---|---|---|
| N = 9034 | N = 7117 (78.8) | N = 1627 (18.0) | N = 290 (3.2) | ||
| Gender, n (%) | |||||
| Male | 2508 (27.8) | 2003 (79.9) | 386 (15.4) | 119 (4.7) | <.0001 |
| Female | 6526 (72.2) | 5114 (78.4) | 1241 (19.0) | 171 (2.6) | |
| Age in yr, median (IQR) | 39 (32–48) | 40 (32–48) | 37 (29–46) | 38 (17–48) | <.0001 |
| Age groups, n (%) | |||||
| Children | 222 (2.5) | 82 (36.9) | 85 (38.3) | 55 (24.8) | |
| Adolescents | 227 (2.5) | 138 (60.8) | 58 (25.5) | 31 (13.7) | <.0001 |
| Adults | 8585 (95.0) | 6897 (80.3) | 1484 (17.3) | 204 (2.4) | |
| Duration on cART in month, median (IQR) | 24 (12–72) | 24 (12–72) | 36 (12–72) | 84 (24–156) | <.0001 |
| Duration on cART in mo | |||||
| 6–12 | 4013 (44.4) | 3271 (81.5) | 672 (16.7) | 70 (1.7) | <.0001 |
| 13–24 | 655 (7.3) | 522 (79.7) | 123 (18.8) | 10 (1.5) | |
| 25–36 | 672 (7.4) | 553 (82.3) | 105 (15.6) | 14 (2.1) | |
| ≥ 48 | 3694 (40.9) | 2771 (75.0) | 727 (19.7) | 196 (5.3) | |
Other first-line ARV [ABC + 3TC + EFV (n = 13), ABC + 3TC + NVP (n = 2), AZT + 3TC + EFV (n = 36), AZT + 3TC + NVP (n = 14), TDF + 3TC + NVP (n = 51), TDF + 3TC + EFV (1511)], dLopinavir based (n = 173) and atazanavir based (n = 117).
3TC = lamivudine, ART = antiretroviral therapy, ARV = antiretroviral, ATVr = ritonavir boosted atazanavir, cART: combined antiretroviral therapy, EFV = efavirenz, IQR = interquartile range, LPVr = ritonavir boosted lopinavir, TDF = tenofovir disoproxil fumarate.
*
P value for virological success at < 1000 copies/M.
†
Percentages in this column represent column percentage.
‡
Percentages in this column represents row percentage.